Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Müller

Showing results (581-590 of 651) with videos related to

Pageof 66
Sort By:
Cell Stem Cell|May 8, 2026
Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AMLAlexander Waclawiczek, Aino-Maija Leppä, Simon Renders, et al.
Nature Cancer|February 5, 2022
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry responseMarina Scheller, Anne Kathrin Ludwig, Stefanie Göllner, et al.
Leukemia|July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsEHartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
Scientific Reports|February 19, 2026
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacyKathrin Hessling, Caroline Brand, Christian Schwöppe, et al.
Nature Cell Biology|June 27, 2017
AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemiaFengbiao Zhou, Yi Liu, Christian Rohde, et al.
Cell Stem Cell|April 25, 2023
Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemiaSergi Beneyto-Calabuig, Anne Kathrin Merbach, Jonas-Alexander Kniffka, et al.
Trials|October 7, 2020
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trialMaike Janssen, Ulrike Schäkel, Carine Djuka Fokou, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Nature Medicine|June 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Blood|December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AMLJad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
Pageof 66

Showing results (581-590 of 651) with videos related to

Sort By:
Pageof 66
Cell Stem Cell|May 8, 2026
Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AMLAlexander Waclawiczek, Aino-Maija Leppä, Simon Renders, et al.
Nature Cancer|February 5, 2022
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry responseMarina Scheller, Anne Kathrin Ludwig, Stefanie Göllner, et al.
Leukemia|July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsEHartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.
Scientific Reports|February 19, 2026
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacyKathrin Hessling, Caroline Brand, Christian Schwöppe, et al.
Nature Cell Biology|June 27, 2017
AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemiaFengbiao Zhou, Yi Liu, Christian Rohde, et al.
Cell Stem Cell|April 25, 2023
Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemiaSergi Beneyto-Calabuig, Anne Kathrin Merbach, Jonas-Alexander Kniffka, et al.
Trials|October 7, 2020
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trialMaike Janssen, Ulrike Schäkel, Carine Djuka Fokou, et al.
Leukemia|December 7, 2023
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patientsElias K Mai, Thomas Hielscher, Uta Bertsch, et al.
Nature Medicine|June 25, 2026
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialMarc S Raab, Niels Weinhold, K Martin Kortüm, et al.
Blood|December 12, 2022
Overlapping features of therapy-related and de novo NPM1-mutated AMLJad Othman, Manja Meggendorfer, Enrico Tiacci, et al.
Pageof 66